Apollo Hospitals Enterprise Limited issued additional clarifications on June 19, 2026 regarding the proposed Composite Scheme of Arrangement involving Apollo Hospitals Enterprise Limited, Apollo Healthco Limited, Keimed Private Limited, and Apollo Healthtech Limited. The filing provides further details on governance matters, promoter commitments on nominee director rights, and proposed amendments to Apollo Healthtech's Articles of Association.
The promoter and promoter group of Apollo Healthtech committed to waiving nomination rights when individual shareholding falls below 5%. Rasmeli Limited and the promoter group separately committed to waiving nomination rights when shareholding falls below 10%. A tiered framework caps maximum nominee directors based on aggregate shareholding: up to 2 directors for holdings between 10% and below 15%, up to 3 directors for 15% to below 25%, up to 4 directors for 25% to below 35%, and up to 5 directors for holdings of 35% and above.
Apollo Healthtech's Articles of Association will be amended after the Scheme becomes effective to incorporate these provisions. The company will seek separate shareholder approval for the proposed amendment of the Articles following Scheme effectiveness.
Apollo Hospitals stated the Scheme represents an important step in unlocking value for shareholders by enabling the separation and independent listing of Apollo Healthtech Limited. The Board believes Apollo Healthtech will gain sharper strategic focus, greater operational flexibility, enhanced capital allocation ability, and clearer visibility for investors into its performance and growth potential.
So long as Apollo Healthtech has an executive chairperson, at least half of its Board will be constituted of independent directors in accordance with applicable law. Apollo Hospitals continues to seek shareholder support for the Scheme.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.